Physician profile
Jason E Boyatt
NPI 1265547624
$15,065.47
in general payments reported to CMS, 2019-2025
22 companies · $2,218 in 2025
The $2,218 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,773 · 2020: $1,009 · 2021: $1,093 · 2022: $1,818 · 2023: $2,228 · 2024: $1,927 · 2025: $2,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,348 · Travel and Lodging: $23.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,348.14 |
| Travel and Lodging | $23.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $5,964.34 | 2021-2025 | Linq II, Micra, Selectsecure |
| Abbott Laboratories | $3,695.14 | 2019-2025 | Ensite Precision, Dragonfly Opstar, Optis |
| Medtronic Vascular, INC. | $3,279.37 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $646.10 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $193.42 | 2019-2025 | Repatha |
| Lundbeck LLC | $159.26 | 2019 | |
| Janssen Pharmaceuticals, INC | $152.20 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $149.64 | 2019-2020 | |
| Edwards Lifesciences Corporation | $143.41 | 2024 | Sapien 3 Ultra Resilia |
| Novartis Pharmaceuticals Corporation | $140.33 | 2019 | |
| Sanofi-Aventis U.S. LLC | $81.14 | 2019 | |
| Pfizer INC. | $79.69 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $68.10 | 2019 | |
| Irhythm Technologies, INC. | $65.73 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $60.87 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Portola Pharmaceuticals, LLC | $47.06 | 2019 | |
| Boston Scientific Corporation | $40.99 | 2019-2023 | |
| Amarin Pharma, INC. | $35.53 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $18.58 | 2019 | |
| W. L. Gore & Associates, INC. | $16.88 | 2019 | |
| Atricure, INC. | $16.17 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Boyatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.